{"id":130070,"date":"2022-11-03T01:57:16","date_gmt":"2022-11-03T01:57:16","guid":{"rendered":"https:\/\/fin2me.com\/?p=130070"},"modified":"2022-11-03T01:57:16","modified_gmt":"2022-11-03T01:57:16","slug":"pfizer-raises-2022-covid-19-vaccine-revenue-outlook","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/pfizer-raises-2022-covid-19-vaccine-revenue-outlook\/","title":{"rendered":"Pfizer Raises 2022 COVID-19 Vaccine Revenue Outlook"},"content":{"rendered":"
Pfizer (US:PFE) on Tuesday lifted its revenue outlook for the year, saying that it will have about $2 billion more COVID-19 vaccine sales than previously expected and now sees\u00a0the Comirnaty vaccine generating\u00a0$34 billion in sales this year.<\/p>\n
It now expects the full year 2022 revenue of $99.5 billion to $102.0 billion and said its business is growing despite negative fallout from the rising US dollar as its operations improved despite seeing a hit from a stronger dollar.<\/p>\n
The company also said Tuesday that its third quarter sales fell 5.8% in the third quarter, driven by some COVID-19 vaccine delivery problems in the European Union.<\/p>\n
For the third quarter, sales fell 5.8%, or $1.4 billion, to $22.6 billion, due to an 87% decline in Covid-19 vaccine sales outside the U.S., Pfizer said Tuesday.<\/p>\n
Pfizer said third quarter global vaccine sales fell to $4.4 billion, down from nearly $13 billion a year ago but topped Wall Street analysts’ forecast sales of $2.6 billion.<\/p>\n
Among other Pfizer products,\u00a0 revenue for breast cancer treatment Ibrance dropped 7% to roughly $1.3 billion, while Xeljanz dropped by 18% to $502 million.<\/p>\n
Pfizer expects its COVID-19 products to “remain multibillion-dollar revenue generators for the foreseeable future, which should serve as a buffer for any unforeseen challenges with other products in our portfolio,” Pfizer Chief Executive Albert Bourla said. He said that Pfizer continues to update its portfolio of Covid-19 treatments.<\/p>\n
Regarding the rest of the third quarter results, Pfizer reported net income of\u00a0$8.6 billion, or $1.51 a share, compared with $8.1 billion, or $1.42 a share, for the previous year. Absent special items, the drug company’s earnings came in at $1.78 a share. Analysts polled had been expecting $1.39 a share.<\/p>\n
“We believe we not only can overcome these expected declines but also can potentially generate strong growth through the end of the decade,” Bourla said.<\/p>\n
This article originally appeared on Fintel<\/i><\/p>\n
Sponsored: Find a Qualified Financial Advisor<\/b><\/p>\n
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.<\/p>\n